Benzamide, 2-[(butylsulfonyl)amino]-N-[(1R)-1-(6-methoxy-3-pyridinyl)propyl]- manufacturers
- AVE1231
-
- $158.00 / 1mg
-
2025-11-09
- CAS:767334-89-4
- Min. Order:
- Purity: 98.03%
- Supply Ability: 10g
|
| | Benzamide, 2-[(butylsulfonyl)amino]-N-[(1R)-1-(6-methoxy-3-pyridinyl)propyl]- Basic information |
| | Benzamide, 2-[(butylsulfonyl)amino]-N-[(1R)-1-(6-methoxy-3-pyridinyl)propyl]- Chemical Properties |
| density | 1.223±0.06 g/cm3(Predicted) | | pka | 8.04±0.10(Predicted) | | form | Solid | | color | White to off-white |
| | Benzamide, 2-[(butylsulfonyl)amino]-N-[(1R)-1-(6-methoxy-3-pyridinyl)propyl]- Usage And Synthesis |
| Uses | AVE1231 (A293) is a dual-pore potassium channel TASK-1 inhibitor. AVE1231 blocks carbamoylcholine chloride (HY-B1208)-activated IKACh (IC50=8.4 μM). AVE1231 can be used in the study of arrhythmias and atrial fibrillation[1][2]. | | References | [1] Wiedmann F, et al. Identification of the A293 (AVE1231) binding site in the cardiac two-pore-domain potassium channel TASK-1: a common low affinity antiarrhythmic drug binding site[J]. Cellular Physiology & Biochemistry (Cell Physiol Biochem Press GmbH & Co. KG), 2019, 52(5). DOI:10.33594/000000083
[2] Wirth K J, et al. In vitro and in vivo effects of the atrial selective antiarrhythmic compound AVE1231[J]. Journal of cardiovascular pharmacology, 2007, 49(4): 197-206. DOI:10.1097/FJC.0b013e318032002f |
| | Benzamide, 2-[(butylsulfonyl)amino]-N-[(1R)-1-(6-methoxy-3-pyridinyl)propyl]- Preparation Products And Raw materials |
|